ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Generic Drug

Also written as “Enter a brief, descriptive name for the intervention. Use a non-proprietary (generic) name, if available. SYS6043” and “Generic 0.5% 5-fluorouracil cream”.

Its studies are mostly in Triple Negative Breast Neoplasms · Keratosis, Actinic, led by 2 companies.

Drug pageGeneric Drug: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Sep 28, 20262 company-led studies, 1 open or runningNext primary completion: Nov 30, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
CSPC Pharmaceutical Groupits history only11 open or runningphase 3since Sep 28, 2026Sep 28, 2026Nov 30, 2028phase 3 · NCT07879911
Spear Pharmaceuticalsits history only10 open or runningphase 3since May 14, 2011May 14, 2011none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of every company. Pick one to see its own:

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 14, 2011First study: phase 3 study in Keratosis, ActinicNew to Spear PharmaceuticalsSpear Pharmaceuticals · NCT01354717 · 377 enrolled
  2. Sep 28, 2026CSPC Pharmaceutical Group’s first study: phase 3 study in Triple Negative Breast NeoplasmsNew to CSPC Pharmaceutical GroupCSPC Pharmaceutical Group · NCT07879911 · 550 planned

Ahead

  1. Nov 30, 2028Primary completion: phase 3 study in Triple Negative Breast NeoplasmsCSPC Pharmaceutical Group · NCT07879911

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07879911Triple Negative Breast Neoplasms3Not yet recruitingCSPC Pharmaceutical GroupNov 30, 2028550
NCT01354717Keratosis, Actinic3CompletedSpear PharmaceuticalsMar 2011377

How it is read

Names in the registry

  • “Enter a brief, descriptive name for the intervention. Use a non-proprietary (generic) name, if available. SYS6043”, 1 entry
  • “Generic 0.5% 5-fluorouracil cream”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.